{"id":20859,"date":"2013-02-01T11:50:58","date_gmt":"2013-02-01T11:50:58","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=20859"},"modified":"2013-08-14T10:45:36","modified_gmt":"2013-08-14T10:45:36","slug":"dolutegravir-submitted-to-eu-us-and-canadian-regulatory-agencies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/20859","title":{"rendered":"Dolutegravir submitted to EU, US and Canadian regulatory agencies"},"content":{"rendered":"<p><strong>On 17 December 2012, ViiV Healthcare issued a press release announcing the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S\/GSK1349572).<\/strong><\/p>\n<p>These submissions are for the treatment of HIV infection in adults and adolescents (children aged 12 years and older).<\/p>\n<p>Reference:<\/p>\n<p>ViiV press release. ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada. 17 December 2012.<br \/>\n<a href=\"http:\/\/www.viivhealthcare.com\/media-room\/press-releases\/2012-12-17\">http:\/\/www.viivhealthcare.com\/media-room\/press-releases\/2012-12-17<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 17 December 2012, ViiV Healthcare issued a press release announcing the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S\/GSK1349572). These submissions are for the treatment of &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-20859","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=20859"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20859\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=20859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=20859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=20859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}